Breathtec Biomedical In-Licenses Technology


VANCOUVER, BC- Apr 13, 2016- Breathtec Biomedical, Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTC PINK: BTHCF) (the “Company” or “Breathtec“), a medical diagnostics company focused on developing, and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases, is pleased to announce the signing of a license agreement dated as of April 11, 2016 (the “License Agreement“) between the Company and Technion Research and Development Foundation Ltd., an Israeli private company and wholly-owned subsidiary of the Technion – Israel Institute of Technology (“Technion“), with respect to a non-exclusive license to certain Technion patents and related know-how in connection with the detection of the following indications from exhaled breath: Streptococcus; Methicillin resistant (MRSA); Staphylococcus; Enterococcus; Vancomycin resistant (VRE); Pneumococcus; Hemophilus influenza (HiB); Chickenpox; and common cold (the “License“).

Subscribe to get the latest news